Development and Global Access to Anti-Tuberculosis Drugs
|
Otsuka Pharmaceutical has been conducting research and development of therapeutic drugs for the elimination of tuberculosis (TB) over the past 40 years. Delamanid, an anti-tuberculosis drug for the treatment of multidrug-resistant pulmonary TB, was approved in Europe and Japan in 2014, and is currently available in more than 125 countries worldwide. In addition, a pediatric dispersion formulation of delamanid will be available from 2022, and access is currently being expanded to more than 35 countries. Eisai has also initiated the clinical development of a new anti-tuberculosis drug candidate, Quabodepistat (OPC-167832), which has a completely different mechanism of action from delamanid and is currently undergoing Phase II clinical trials. |
| Joining the Global Partnership for the Development of Anti-Tuberculosis Drugs |
Eisai is a member of the Tuberculosis Drug Accelerator (TBDA), a partnership supported by the Bill & Melinda Gates Foundation and co-founded by seven global pharmaceutical companies and six research institutions. TBDA is a partnership of seven global pharmaceutical companies and six research institutions, supported by the Bill & Melinda Gates Foundation, to develop a new treatment for tuberculosis (TB) that can cure the disease in one month, as opposed to the existing six-month treatment regimen. |
| Development of Anti-Tuberculosis Drugs |
Eisai is collaborating with the Broad Institute to develop new drugs for tuberculosis. |
| Development of new tuberculosis drugs |
Shionogi considers tuberculosis (TB), one of the world's three major infectious diseases, to be a major theme to be addressed globally, and has focused on the discovery of new anti-tuberculosis drugs in its collaboration with Hsiri and has initiated screening for new anti-tuberculosis drugs in collaboration with external research institutions. |
| Screening and Hit-to-Lead Program for the Control of Infectious Diseases in Developing Countries (GHIT Fund Program) |
Daiichi Sankyo is participating in a GHIT Fund screening program for the discovery of TB drug candidates using a natural product library. In addition, Astellas is conducting joint research to create lead compounds based on promising compounds discovered in the screening program. |
| Discovery of drugs for tuberculosis (GHIT Fund Program) |
In March 2021, Astellas and the TB Alliance conducted a joint research project (the "Screening PJ") for about two years from October 2017 on the discovery of drugs for Mycobacterium tuberculosis. In March 2021, we concluded a joint research agreement with TB Alliance to create lead compounds with improved pharmacological activity, pharmacokinetics, and safety by utilizing the hit compounds obtained from the Screening PJ, and we are continuing our research efforts. |
